Tel: 1-631-626-9181 (USA)    44-207-097-1828 (Europe)


Our promise to you:
Guaranteed product quality, expert customer support.


Lung Cancer

Lung cancer is the leading cause of cancer-related death all over the world. Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). During the last two decades, several chemotherapeutic and molecular target driven agents against angiogenesis and epidermal growth factor (EGF) pathway have been tested in NSCLC with success. More recently, it has been found that around 3–4% of NSCLC patients are driven by a fusion protein of the anaplastic lymphoma kinase (ALK). Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene (KRAS) gene mutations, MET amplification, EML4-ALK rearrangements are widely recognized alterations involved in the pathobiology of lung cancer with clinical impact for NSCLC treatment. Moreover, new oncogenic gene alterations have been identified in NSCLC, including HER2 exon 20 insertion mutations, fibroblast growth factor receptor 1 (FGFR1) amplification, discoidin domain receptor tyrosine kinase 2 (DDR2) mutations, BRAF mutations, RET and ROS1 rearrangements, and alterations of PIK3/AKT/mTOR pathway.

In addition, the identification of activating EGFR mutations and ALK rearrangements as predictive biomarkers for treatment of NSCLC led to further personalization of therapy with EGFR tyrosine kinase inhibitors (EGFR-TKIs) erlotinib, afatinib and gefitinib; and ALK inhibitors, including ceritinib, crizotinib, andalectinib. Furthermore, the possibility to target the molecular components of the PI3K/ AKT/mTOR pathway using specific inhibitors is currently under investigation for NSCLC treatment in both preclinical and clinical setting. Therefore, NSCLC molecular profiling is an important factor in treatment decision making, with a number of emerging oncogenic targets and active targeted agents.

The identification of driver oncogenic mutations and the development of biomarker-guided targeted agents have improved outcomes of patients with NSCLC and revolutionized NSCLC therapeutic strategies. Creative Biogene, as a leading biotechnology company, is able to offer various lung cancer pathway related products including stable cell lines, viral particles and clones for your drug discovery projects.


  1. Fumarola C, et al. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochemical Pharmacology, 2014, 90(3):197-207.
  2. Tomasini P, et al. Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. The Oncologist, 2016:theoncologist.2015-0084.
  3. Alevizakos M, et al. The VEGF pathway in lung cancer. Cancer Chemother Pharmacol, 2013, 72(6):1169-1181.

Quick Inquiry

   Please input "biogene" as verification code.